ORGO Cash-Secured Put Strategy

ORGO (Organogenesis Holdings Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

ORGO (Organogenesis Holdings Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $347.4M, a beta of 1.31 versus the broader market, a 52-week range of 2.04-7.077, average daily share volume of 1.4M, a public-listing history dating back to 2017, approximately 869 full-time employees. These structural characteristics shape how ORGO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.31 indicates ORGO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a cash-secured put on ORGO?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

Current ORGO snapshot

As of May 15, 2026, spot at $2.42, ATM IV 149.50%, IV rank 27.64%, expected move 42.86%. The cash-secured put on ORGO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this cash-secured put structure on ORGO specifically: ORGO IV at 149.50% is on the cheap side of its 1-year range, which means a premium-selling ORGO cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 42.86% (roughly $1.04 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ORGO expiries trade a higher absolute premium for lower per-day decay. Position sizing on ORGO should anchor to the underlying notional of $2.42 per share and to the trader's directional view on ORGO stock.

ORGO cash-secured put setup

The ORGO cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ORGO near $2.42, the first option leg uses a $2.30 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ORGO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ORGO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$2.30N/A

ORGO cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

ORGO cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on ORGO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on ORGO

Cash-secured puts on ORGO earn premium while a trader waits to acquire ORGO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning ORGO.

ORGO thesis for this cash-secured put

The market-implied 1-standard-deviation range for ORGO extends from approximately $1.38 on the downside to $3.46 on the upside. A ORGO cash-secured put lets a trader earn premium while waiting to acquire ORGO at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current ORGO IV rank near 27.64% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ORGO at 149.50%. As a Healthcare name, ORGO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ORGO-specific events.

ORGO cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ORGO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ORGO alongside the broader basket even when ORGO-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on ORGO carry tail risk when realized volatility exceeds the implied move; review historical ORGO earnings reactions and macro stress periods before sizing. Always rebuild the position from current ORGO chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on ORGO?
A cash-secured put on ORGO is the cash-secured put strategy applied to ORGO (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With ORGO stock trading near $2.42, the strikes shown on this page are snapped to the nearest listed ORGO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ORGO cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the ORGO cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 149.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ORGO cash-secured put?
The breakeven for the ORGO cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ORGO market-implied 1-standard-deviation expected move is approximately 42.86%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on ORGO?
Cash-secured puts on ORGO earn premium while a trader waits to acquire ORGO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning ORGO.
How does current ORGO implied volatility affect this cash-secured put?
ORGO ATM IV is at 149.50% with IV rank near 27.64%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related ORGO analysis